Agios/$AGIO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Agios

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Ticker

$AGIO
Primary listing

Industry

Biotechnology

Employees

487

ISIN

US00847X1046

Agios Metrics

BasicAdvanced
$2.1B
3.10
$11.45
0.73
-

What the Analysts think about Agios

Analyst ratings (Buy, Hold, Sell) for Agios stock.

Bulls say / Bears say

Agios Pharmaceuticals received $1.1 billion in milestone payments following the FDA approval of vorasidenib, significantly strengthening its cash position to $1.7 billion as of June 30, 2024. (GlobeNewswire)
The company completed enrollment of the Phase 3 RISE UP study of mitapivat in sickle cell disease, with topline data expected in late 2025, indicating progress in expanding its therapeutic pipeline. (GlobeNewswire)
Analysts have set an average 12-month target price of $56.33 for Agios Pharmaceuticals, suggesting potential upside from its current trading price. (Defense World)
Agios reported a net income loss of $89.29 million in Q1 2025, reflecting ongoing financial challenges. (Google Finance)
The company's sole marketed drug, PYRUKYND® (mitapivat), generated net revenue of $9.0 million in Q3 2024, indicating modest sales performance. (GlobeNewswire)
Agios' mitapivat failed to meet the primary endpoint in a Phase 3 study for pediatric patients with pyruvate kinase deficiency, potentially impacting future revenue growth. (Benzinga)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

Agios Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Agios Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AGIO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs